Peripheral SpA, PsA, uSpA and Diagnostic Boundaries
Separate peripheral phenotype, disease association and diagnostic confidence before choosing a treatment pathway or interpreting a study.
On this page
Start with three separate questions
Peripheral spondyloarthritis is useful only when the label tells another clinician what is inflamed, why a spondyloarthritis framework is credible, and what remains uncertain. Those are different questions. An adult may have established inflammatory knee synovitis, a compelling SpA pattern and no currently identifiable psoriasis, inflammatory bowel disease or triggering infection. Another may have heel pain and an incidental positive HLA-B27 result without demonstrated inflammatory disease. Describing both as “undifferentiated SpA” erases the most important distinction between them.
Document the current phenotype, the disease context and the degree of diagnostic confidence separately. The practical purpose is to make treatment and reassessment intelligible. A sufficiently credible inflammatory diagnosis may justify action before every feature is settled; uncertainty still belongs in the record rather than being concealed by a broad code.
Peripheral is a phenotype, not a guarantee of isolation
The peripheral phenotype comprises inflammatory arthritis, enthesitis, dactylitis, or a combination. It describes the dominant clinical problem, not a prohibition on axial involvement. Back symptoms require their own assessment; a peripheral label must not terminate it. Conversely, an axial diagnosis does not explain every painful peripheral structure. A patient with axSpA can also have a torn tendon, gout or septic arthritis.
The ASAS peripheral classification framework recognizes peripheral entry manifestations with additional SpA features. It was developed for research classification in a selected referral setting. Its existence does not make a criteria-positive result a stand-alone clinical diagnosis. Clinical reasoning still requires confirmation that the entry manifestation is real and that a better explanation has been considered. [1]
What “undifferentiated” can mean
Historical uSpA terminology covered people who did not fit the older named categories. Contemporary use is less uniform. It may describe a reasonably established SpA syndrome without a defined association, an incomplete phenotype, or an old diagnosis carried forward after the dominant phenotype has changed. These situations should not be treated as interchangeable.
- Established peripheral SpA, association not yet defined: objective inflammation and the total pattern support SpA, but no specific associated disease has been identified.
- Suspected SpA: a working hypothesis remains under evaluation. State the evidence for it and the competing explanation.
- Historical uSpA: retain relevant history, but re-describe current axial and peripheral manifestations.
- Undifferentiated inflammatory arthritis: inflammation is established, but its family is not. This is not automatically SpA.
“Undifferentiated” therefore does not mean early, mild, harmless or destined to become a named subtype. Duration and severity are independent variables. Nor does it establish that a prior clinician was wrong when a later feature clarifies the diagnosis.
Where PsA fits
Psoriatic arthritis and peripheral SpA overlap substantially, but the terms answer different questions. PsA supplies a disease-specific context; pSpA supplies a peripheral manifestation framework. Current psoriasis, prior psoriasis, family history, nail disease and the pattern of articular disease deserve deliberate assessment. Absence of obvious skin plaques today does not by itself settle the issue.
CASPAR offers a research classification structure for PsA in the setting of inflammatory articular disease. It includes features beyond current psoriasis. It should not be turned into a points-based replacement for confirming inflammation or distinguishing nail psoriasis from a fungal or traumatic nail disorder. [2] A person with credible PsA should follow the PsA treatment and evidence pathway, while retaining precise documentation of arthritis, enthesitis and other active domains.
Route by the clinical context
| Finding that becomes established | How the working description changes | Next clinical task |
|---|---|---|
| Psoriasis or a convincing psoriatic phenotype | PsA may become the more informative disease label. | Assess skin, nails and musculoskeletal domains together. |
| Inflammatory bowel disease | The IBD-associated SpA pathway becomes relevant. | Coordinate joint and bowel treatment; define which organ is active. |
| A plausible preceding infection | A reactive arthritis interpretation may strengthen. | Distinguish an antecedent trigger from current joint infection and other causes. |
| Dominant axial disease | An axSpA pathway may better organize care. | Assess axial disease without deleting the peripheral record. |
| Childhood-onset disease | The pediatric diagnosis becomes part of an adult transition history. | Recover prior phenotype, imaging, treatment and complications. |
Do not confuse breadth of classification with breadth of evidence
A trial labeled “pSpA” may exclude PsA, include people with psoriasis, emphasize synovitis, or enroll very early disease. These populations are not made identical by sharing ASAS entry criteria. Before applying an effect estimate, check the inclusion and exclusion criteria, proportions with associated disease, duration, active domains and prior treatment. The question is whether the patient resembles the studied population in the characteristics that matter for the decision.
ASAS-PerSpA demonstrated extensive overlap of peripheral manifestations across clinician-assigned SpA subtypes. This supports careful phenotyping; it does not demonstrate identical treatment effects across all subtypes. [3] In particular, treatment success in PsA cannot silently become direct proof for non-psoriatic pSpA.
A useful diagnostic formulation
An illustrative formulation is: “Predominantly peripheral inflammatory SpA, currently oligoarticular synovitis with Achilles enthesitis; no established psoriasis or IBD; no convincing infection trigger; intermittent back symptoms under separate evaluation.” Add the observations supporting the diagnosis, the principal unresolved alternative and the planned reassessment trigger. This is more actionable than adding increasingly broad synonyms.
At follow-up, ask whether the disease has changed, the information has changed, or the original hypothesis has weakened. New objective findings can increase confidence. Persistent pain without concordant inflammatory findings should prompt a fresh assessment of mechanism, not automatic escalation of the label. Symptom improvement with an NSAID or glucocorticoid alone cannot adjudicate the diagnosis.
Clinical checkpoint
Before leaving this chapter, the record should answer: what is demonstrably inflamed; which SpA associations are established rather than suspected; whether axial disease is dominant; and which observation would change the working diagnosis. This framework remains useful even if classification terminology changes.
Evidence in context
Source status checked October 6, 2026. Population applicability and publication maturity are separate judgments.
Scrollable evidence table
| Source | Population and phenotype | Design and status | Applicability | Clinical implication | Important limitation | Last checked |
|---|---|---|---|---|---|---|
| ASAS peripheral criteria [1] | Newly referred patients with peripheral entry manifestations | Classification development; peer-reviewed | Direct to classification, not a diagnostic reference standard | Use the correct framework and entry phenotype | Selected referral population; clinician diagnosis used as reference | 2026-10-06 |
| CASPAR [2] | PsA and other inflammatory arthropathies | Classification development; peer-reviewed | PsA-specific context | Assess psoriasis-related features beyond visible plaques | Does not replace individual differential diagnosis | 2026-10-06 |
| ASAS-PerSpA [3] | Clinician-diagnosed SpA, including PsA | Cross-sectional; peer-reviewed | Mixed SpA population | Expect overlapping manifestations | Cannot establish longitudinal progression or treatment equivalence | 2026-10-06 |